Low-dose mithramycin exerts its anticancer effect via the p53 signaling pathway and synergizes with nutlin-3 in gynecologic cancers

Cancer Science

Volumn 101, Issue 6, 2010, Pages 1387-1395

  Ohgami, Tatsuhiro ^a   Kato, Kiyoko ^b   Kobayashi, Hiroaki ^a   Sonoda, Kenzo ^a   Inoue, Takafumi ^a   Yamaguchi, Shin ichiro ^a   Yoneda, Tomoko ^a   Wake, Norio ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MITHRAMYCIN; NUTLIN 3; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; PUMA PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UPREGULATION;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; IMIDAZOLES; PIPERAZINES; PLICAMYCIN; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; SP1 TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77954157430     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01543.x     Document Type: Article

References (35)

1. Momand J, Wu HH, Dasgupta G. MDM2 - master regulator of the p53 tumor suppressor protein. Gene 2000, 242:15-29.
2. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000, 408:307-10.
3. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature 1993, 362:857-60.
4. Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 2003, 13:49-58.
5. Freedman DA, Levine AJ. Regulation of the p53 protein by the MDM2 oncoprotein - thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res 1999, 59:1-7.
6. Chang CJ, Freeman DJ, Wu H. PTEN regulates Mdm2 expression through the P1 promoter. J Biol Chem 2004, 279:29841-8.
7. Phillips A, Darley M, Blaydes JP. GC-selective DNA-binding antibiotic, mithramycin A, reveals multiple points of control in the regulation of Hdm2 protein synthesis. Oncogene 2006, 25:4183-93.
8. Deb SP. Cell cycle regulatory functions of the human oncoprotein MDM2. Mol Cancer Res 2003, 1:1009-16.
9. Ries S, Biederer C, Woods D. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 2000, 103:321-30.
10. Bond GL, Hu W, Bond EE. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004, 119:591-602.
11. Levav-Cohen Y, Haupt S, Haupt Y. Mdm2 in growth signaling and cancer. Growth Factors 2005, 23:183-92.
12. Oehler MK, Brand A, Wain GV. Molecular genetics and endometrial cancer. J Br Menopause Soc 2003, 9:27-31.
13. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathway of tumorigenesis. Hum Pathol 1995, 26:1268-74.
14. Ho SM. Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol 2003, 1:73-80.
15. Gudas JM, Nguyen H, Klein RC, Katayose D, Seth P, Cowan KH. Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells. Clin Cancer Res 1995, 1:71-80.
16. Sheikh MS, Shao ZM, Hussain A, Fontana JA. The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res 1993, 53:3226-8.
17. Imamura T, Arima T, Kato H, Miyamoto S, Sasazuki T, Wake N. Chromosomal deletions and K-ras gene mutations in human endometrial carcinomas. Int J Cancer 1992, 51:47-52.
18. Enomoto T, Weghorst CM, Inoue M, Tanizawa O, Rice JM. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 1991, 139:777-85.
19. Høgdall EV, Høgdall CK, Blaakaer J. K-ras alterations in Danish ovarian tumour patients. From the Danish " Malova" Ovarian Cancer study. Gynecol Oncol 2003, 89:31-6.
20. Suga S, Kato K, Ohgami T. An inhibitory effect on cell proliferation by blockage of the MAPK/estrogen receptor/MDM2 signal pathway in gynecologic cancer. Gynecol Oncol 2007, 105:341-50.
21. Jayasuriya H, Lingham RB, Graham P. Durhamycin A, a potent inhibitor of HIV Tat transactivation. J Nat Prod 2002, 65:1091-5.
22. Koutsodontis G, Kardassis D. Inhibition of p53-mediated transcriptional responses by mithramycin A. Oncogene 2004, 23:9190-200.
23. Gause GF. Olivomycin, mithramycin, chromomycin: three related cancerostatic antibiotics. Adv Chemother 1965, 2:179-95.
24. Brown JH, Kennedy BJ. Mihramycin in the treatment of disseminated testicular neoplasms. N Engl J Med 1965, 272:111-8.
25. Koller CA, Miller DM. Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea. N Engl J Med 1986, 315:1433-8.
26. Albertini V, Jain A, Vignati S. Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy. Nucleic Acids Res 2006, 34:1721-34.
27. Phelps M, Phillips A, Darley M, Blaydes JP. MEK-ERK signaling controls Hdm2 oncoprotein expression by regulating hdm2 mRNA export to the cytoplasm. J Biol Chem 2005, 280:16651-8.
28. Iwakuma T, Lozano G. MDM2, an introduction. Mol Cancer Res 2003, 1:993-1000.
29. Marine JC, Dyer MA, Jochemsen AG. MDMX: from bench to bedside. J Cell Sci 2007, 120:371-8.
30. Vassilev LT, Vu BT, Graves B. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-8.
31. Ferrante RJ, Ryu H, Kubilus JK. Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. J Neurosci 2004, 24:10335-42.
32. Kennedy BJ, Sandberg-Wollheim M, Loken M, Yarbro JW. Studies with tritiated mithramycin in C3H mice. Cancer Res 1967, 27:1534-8.
33. Lau LM, Nugent JK, Zhao X, Irwin MS. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene 2008, 27:997-1003.
34. VanderBorght A, Valckx A, Van Dun J. Effect of an hdm-2 antagonist peptide inhibitor on cell cycle progression in p53-deficient H1299 human lung carcinoma cells. Oncogene 2006, 25:6672-7.
35. Paris R, Henry RE, Stephens SJ, McBryde M, Espinosa JM. Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation. Cell Cycle 2008, 7:2427-33.